News Scotland's Opdivo decision sparks funding row Patients in Scotland will receive lung cancer drug, those in England will not.
News Potential lung cancer use for Novartis' melanoma combo New trial suggests use in lung cancer with same mutation.
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
